Preclinical evaluation of hematoporphyrin derivative for the treatment of intraocular tumors: a preliminary report.
Preclinical evaluation of hematoporphyrin derivative for the treatment of intraocular tumors: a preliminary report.
复制标题
血卟啉衍生物治疗眼内肿瘤的临床前评价：初步报告。
DOI：
10.1007/978-1-4684-4406-3_11
复制
发表时间：
1983
影响因子：
--
通讯作者：
Murphree,AL
中科院分区：
文献类型：
--
作者：
Gomer,CJ;Szirth,BC;Doiron,DR;Jester,JV;Lingua,RW;Mark,C;Benedict,WF;Murphree,AL
治疗方式，如外部光束放射治疗，钴斑，光凝或冷冻治疗，以保留有用的视力在眼部肿瘤患者只提供有限的成功。在许多情况下，为了防止肿瘤扩散，有必要进行眼球摘除术（1）。眼内肿瘤对可见光的可及性和眼睛的优良光学特性表明，血卟啉衍生物光辐射疗法（HPD PRT）可能被证明是成功治疗眼内和眼周恶性肿瘤的重要进展。由于眼睛对光的极端敏感性以及正常眼部结构不可修复的损伤可能导致的视力丧失，我们正在进行临床前研究，旨在评估HPD PRT作为治疗眼部肿瘤的主要临床方式的疗效。
Treatment modalities such as external beam radiation therapy, cobalt plaques, photocoagulation or cryotherapy for preservation of useful vision in patients with ocular tumors offer only limited success. In many cases enucleation is necessary in order to prevent tumor spread (1). The accessibility of intraocular tumors to visible light and the excellent optical properties of the eye suggest that hemato-porphyrin derivative photoradiation therapy (HPD PRT) may prove to be an important advancement in the successful management of intraocular and periocular malignancies. Due to the extreme sensitivity of the eye to light and the possible loss of vision resulting from non-repairable damage to normal ocular structures, we are performing preclinical studies designed to evaluate the efficacy of HPD PRT as a primary clinical modality for treating ocular tumors.